Investment objective of the scheme is to provide long term capital appreciation by investing predominantly in equity/equity related instruments of the companies in the Pharma&Healthcare sectors in India. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -7.42% | -6.38% | 5.15% | 4.71% | -0.23% | -0.3% | 15.22% | 16.64% | 11.84% | 12.5% | 11% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -7.42% | -6.38% | 5.15% | 4.71% | -0.23% | -0.6% | 53.02% | 85.14% | 75.04% | 224.73% | 209.23% |
| Rank within category | 9/19 | 18/18 | 18/18 | 18/18 | 17/17 | 13/14 | 10/12 | 8/10 | 6/9 | 4/4 | N/A |
| Sector Funds | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yearly returns | -14.65% | 4.65% | -2.62% | 5.51% | 64.38% | 19.07% | -8.04% | 36.58% | 40.4% | -4.92% | 2.37% |
| Q1 returns | -6.55% | 6.42% | -6.86% | 4.15% | -2.98% | -2.68% | -4.64% | -4.19% | 10.75% | -9.86% | -6.98% |
| Q2 returns | -0.32% | -4.38% | 2.44% | -4.66% | 25.07% | 16.84% | -10.36% | 15.19% | 4.62% | 5.44% | 15.06% |
| Q3 returns | 1.99% | -6.15% | 6.8% | 1.78% | 21.78% | 3.71% | 8.14% | 11.11% | 18.85% | -0.66% | 0.12% |
| Q4 returns | -10.17% | 9.58% | -4.44% | 4.39% | 11.24% | 0.97% | -0.52% | 11.38% | 1.96% | 0.7% | -4.47% |
0.25% on or before 30D
| Alpha | 0.898837 |
| Beta | 0.6931 |
| Sharpe Ratio | 0.230518 |
| Sortino Ratio | 0.472504 |
| R-Squared | 0.3652 |
| Tracking Error | 3.4607 |
| Downside Risk | 18.3684 |
| Std. Deviation (Annualised) | 14.272 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth Current | -7.42% | -6.38% | 5.15% | 4.71% | -0.23% | 15.22% | 11.84% | 12.5% | 11% | 1,511.49 | 2.37 | 0.23 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.99% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.94% |
| Healthcare Global Enterprises Ltd. | Healthcare Services | Domestic Equities | 5.92% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.68% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.65% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 4.36% |
| Rainbow Children's Medicare Ltd. | Healthcare Services | Domestic Equities | 4.30% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.22% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.76% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 3.71% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.14% |
| Bayer CropScience Ltd. | Fertilizers & Agrochemicals | Domestic Equities | 2.96% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 2.85% |
| Procter & Gamble Health Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.75% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.60% |
| PI Industries Ltd. | Fertilizers & Agrochemicals | Domestic Equities | 2.59% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.57% |
| Pfizer Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.50% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.36% |
| FDC Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.24% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 1.95% |
| Acutaas Chemicals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.95% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 1.76% |
| Aster DM Quality Care Ltd. | Healthcare Services | Domestic Equities | 1.67% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.63% |
| Natco Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.51% |
| Sumitomo Chemical India Ltd. | Fertilizers & Agrochemicals | Domestic Equities | 1.38% |
| Gillette India Ltd. | Personal Products | Domestic Equities | 1.23% |
| Navin Fluorine International Ltd. | Chemicals & Petrochemicals | Domestic Equities | 1.18% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.91% |
| Prasol Chemicals Ltd. | Chemicals & Petrochemicals | Domestic Equities | 0.88% |
| Symbiotec Pharmalab Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.87% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.77% |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.76% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.69% |
| Dr. Agarwal's Health Care Ltd. | Healthcare Services | Domestic Equities | 0.68% |
| Manipal Health Enterprises Ltd. | Healthcare Services | Domestic Equities | 0.59% |
| Zim Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.58% |
| Sanofi Consumer Healthcare India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.57% |
| Molbio Diagnostics Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 0.54% |
| Gujarat Fluorochemicals Ltd. | Chemicals & Petrochemicals | Domestic Equities | 0.53% |
| I) REPO | Cash & Cash Equivalents and Net Assets | 0.19% | |
| CASH / NET CURRENT ASSET | Cash & Cash Equivalents and Net Assets | 0.08% | |
| Jubilant Pharmova Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.00% |
| Total | 100.00% | ||
With over eight years of industry experience across buy-side and sell-side firms, Mr. Rajat Srivastava brings strong equity research expertise to Tata Asset Management. As an Assistant Fund Manager and Research Analyst, he focuses on the Healthcare and Chemicals sectors, contributing to informed investment decisions and strategic insights in these areas. Before joining Tata Asset Management, Mr. Srivastava held positions at Incred Asset Management, Kotak Investment Banking, and Motilal Oswal Institutional Equities, where he further honed his analytical and financial acumen. Mr. Srivastava holds a Post Graduate Diploma in Management (PGDM) from IMT Ghaziabad.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
